U.S. Tobacco Stock News

NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

3 US Real Estate Stocks Investors Are Watching Before The Next Fed Decision

With the June 2026 CPI print landing just weeks before a key Federal Reserve meeting, interest rate expectations are again front and center for anyone watching US real estate stocks. Rate sensitive property companies can see their borrowing costs and valuations shift quickly when inflation surprises. This article breaks down how that backdrop connects to three stocks from a US Rate Sensitive Real Estate screener and why their reactions could matter for your portfolio. The three stocks below...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher Scientific (TMO) Showcases Diagnostics Momentum, Is The Valuation Upside Already Priced In?

Thermo Fisher Scientific event puts specialty diagnostics in focus Thermo Fisher Scientific (TMO) has put its specialty diagnostics business in the spotlight after showcasing new products and recent U.S. Food and Drug Administration clearances at the ADLM conference in Anaheim in late July 2026. The event highlighted the EXENT Solution for multiple myeloma monitoring and the EliA CTD 13 Screen for autoimmune disease testing, along with software and quality control tools designed to support...
NYSE:STT
NYSE:STTCapital Markets

The Bull Case For State Street (STT) Could Change Following New US$500 Million Perpetual Preferred Issuance

In early August 2026, State Street Corporation amended its Articles of Organization in Massachusetts to codify the terms of its new Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series L, including its US$100,000 per share liquidation preference and placement alongside other preferred series. This legal update followed the completion of a US$500 million offering of perpetual, callable, non-cumulative preferred depositary shares, highlighting an ongoing reshaping of State...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Varonis (VRNS) Is Up 8.9% After Launching AI Agent Access Controls And Raising 2026 Outlook

In early August 2026, Varonis Systems, Inc. launched Agent Intent-Based Access Control within its Atlas platform, adding safeguards that monitor AI agents’ reasoning, tool use, and data access, while also reporting second-quarter revenue of US$180.02 million and updated guidance for continued double-digit revenue growth in 2026. This combination of advanced controls for AI agent behavior and a reinforced growth outlook highlights how Varonis is aligning its data security platform with...
NYSE:WOR
NYSE:WORMachinery

Worthington Enterprises (WOR) Draws Attention On Value, Is It Still 11% Below Fair Value?

Worthington Enterprises stock snapshot after recent trading move Worthington Enterprises (WOR) has drawn investor attention after a recent trading move, with the stock last closing at $58.42. That price comes alongside a value score of 5 and an intrinsic discount of 36.9%. See our latest analysis for Worthington Enterprises. Recent trading fits into a broader picture for Worthington Enterprises, with a 30 day share price return of 10.69% and a year to date share price return of 12.43%. This...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

AGNC’s Premium Valuation And Dividend Debate Might Change The Case For Investing In AGNC (AGNC)

Recent commentary on AGNC Investment Corp. highlights that the mortgage REIT is trading at roughly a 25% premium to its Q2 2026 tangible net book value per share of US$8.58, while its double‑digit dividend yield currently appears supported by net spread income. However, concerns about how rising interest rates, leverage, and macroeconomic pressures could affect the sustainability of that high payout are now a central focus for investors assessing AGNC’s risk profile. We’ll now examine how...
NYSE:JPM
NYSE:JPMBanks

JPMorgan Chase Stock And 2 Retirement Income Picks For Investors Staying In Equities

Retirement has quietly entered a new phase. Instead of shifting almost everything into cash and bonds at age 65, many investors are being encouraged to keep 40% to 80% in equities to help manage inflation and longer lifespans. As a result, a larger share of retirement money could flow toward certain stocks and funds, while others may see less attention. This article examines three stocks from our Retirement Income Growth Stocks With Equity Allocation Tailwinds screener that stand out as...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

Why MannKind (MNKD) Is Up 5.1% After Positive Inhaled Nintedanib Data Despite Q2 Net Loss

MannKind Corporation recently reported its second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier while moving from a small net profit to a net loss of US$19.03 million. A few days earlier, MannKind released positive Phase 1b data for its inhaled nintedanib in idiopathic pulmonary fibrosis, underscoring the potential of its Technosphere platform to extend into high-need lung indications beyond its current commercial products. We’ll now...
NYSE:SPOT
NYSE:SPOTEntertainment

Spotify (SPOT) Stock Looks Below Fair Value As Markets Stay Cautious

Spotify Technology has fallen sharply over the past year but still screens as attractively priced on Simply Wall St's intrinsic value checks, with the Discounted Cash Flow (DCF) estimate pointing to a meaningful gap to the current share price even as market multiples suggest the stock is closer to fair. Spotify Technology has returned about 252% over the past 3 years, which means investors are now weighing a strong multi year run against whether the current price still offers enough...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Is Up 10.6% After Advancing Oral Obesity Drug Into Phase 3 Trial

Structure Therapeutics recently advanced its obesity portfolio by dosing the first patients in its Phase 3 ACCOMPLISH trial of oral aleniglipron and appointing veteran commercial leader John Berrios as Chief Commercial Officer. The combination of late-stage trial progress and leadership drawn from major obesity and diabetes franchises highlights Structure’s focus on preparing aleniglipron for potential large-scale commercialization. Next, we’ll examine how the Phase 3 launch of aleniglipron...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run

UroGen Pharma stock has delivered very strong share price returns over the past five years, yet its current valuation checks and market multiples now suggest the shares are closer to fairly priced than a clear bargain. UroGen Pharma has returned about 210% over the last 5 years, which puts recent gains front and center when judging whether the current price already reflects much of that success. Expectations around UroGen Pharma’s ability to grow revenue and eventually convert its pipeline...
NYSE:BRK.A
NYSE:BRK.ADiversified Financial

Berkshire Hathaway Stock Signals Fresh Value Ideas In US Large Caps

Berkshire Hathaway’s renewed buying spree under Greg Abel, including a US$10b move into Alphabet and billions more in equities, has turned a quiet market narrative into something far more exciting for stock pickers. When a giant like Berkshire starts writing big checks again, many investors worry about missing the next wave of opportunity. This article looks at three stocks tied to that shift and how this renewed confidence could matter for your portfolio decisions. Berkshire Hathaway...
NYSE:GLP
NYSE:GLPOil and Gas

Is Global Partners (GLP) Fully Valued After Strong Q2 Results And A Distribution Update?

Global Partners (GLP) is back on investor radar after reporting second quarter 2026 results, with higher sales, net income, earnings per unit, and a recent cash distribution announcement drawing fresh attention to the stock. See our latest analysis for Global Partners. The latest earnings release and July cash distribution decision have arrived alongside a solid share price trend for Global Partners, with the stock up 18.74% year to date on a share price return basis and a 5.09% total...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Meta (META) Stock Looks Cheap On Cash Flow But Fair On Earnings

Meta Platforms stock has pulled back this year even though the valuation work still leans positive, with the Discounted Cash Flow (DCF) intrinsic value estimate and earnings based multiples both pointing to an undervalued share price relative to those fundamentals. Meta Platforms has returned about 98% over the past 3 years, which means many investors are now asking whether the recent share price leaves enough room for further value to be realised. Heavy investment in AI infrastructure and...
NasdaqGS:IDCC
NasdaqGS:IDCCSoftware

Why InterDigital (IDCC) Is Up 13.0% After Raising 2026 Guidance Despite Weaker Q2 Results – And What's Next

In late July 2026, InterDigital, Inc. reported that second-quarter sales fell to US$260.17 million and net income to US$116.37 million, yet also updated investors on ongoing share repurchases. Despite weaker quarterly results, the company raised its full-year 2026 revenue and earnings guidance, signaling management confidence in a stronger second half. Next, we’ll examine how InterDigital’s upgraded full-year 2026 guidance reshapes the existing investment narrative around its earnings...
NasdaqGS:CVCO
NasdaqGS:CVCOConsumer Durables

Is Cavco Industries (CVCO) Still Undervalued As Record Revenue And Backlog Grow?

Cavco Industries (CVCO) is back in focus after reporting record quarterly revenue alongside a sharply higher order backlog, while margin pressure and the new ROAD to Housing Act give investors fresh factors to weigh. See our latest analysis for Cavco Industries. The share price reaction has been steady rather than explosive. Cavco Industries has a 90 day share price return of 22.23% and a 1 year total shareholder return of 30.39%, while the 3 year total shareholder return of 101.83% points to...
NYSE:STNG
NYSE:STNGOil and Gas

The Bull Case For Scorpio Tankers (STNG) Could Change Following Profit Surge And Aggressive Buybacks - Learn Why

In the second quarter of 2026, Scorpio Tankers Inc. reported net income of US$387.54 million and sharply higher earnings per share versus a year earlier, alongside strong first-half results. The company also continued returning cash to shareholders through a US$0.45 quarterly dividend and extensive share repurchases that have retired more than a quarter of its shares since 2023. Next, we’ll examine how this surge in profitability and recent share repurchases interact with Scorpio Tankers’...
NYSE:ULS
NYSE:ULSProfessional Services

UL Solutions (ULS) Is Down 14.7% After Profitability Surges on Q2 2026 Earnings Beat – What's Changed

UL Solutions Inc. has reported past second-quarter 2026 results showing sales of US$816 million versus US$776 million a year earlier, with net income rising to US$246 million from US$91 million and diluted EPS from continuing operations increasing to US$1.21 from US$0.45. An interesting angle for investors is the sharp expansion in profitability, as net income grew far faster than sales, indicating stronger operating efficiency and margin performance over the period. Next, we will examine...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

AeroVironment (AVAV) Stock Looks Close To Fair Value Overall

AeroVironment stock has delivered a strong 3 year run, yet its current valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate indicating about 10.3% upside while market based multiples point to a richer pricing and an overall low value score. AeroVironment has returned 95.2% over the past 3 years, which puts recent share price weakness into the context of a much stronger longer term move. The recent collaboration with Applied Intuition on uncrewed teaming...
NYSE:HNGE
NYSE:HNGEHealthcare

Hinge Health (HNGE) Earnings And New Care Push Put Valuation Back In Focus

Hinge Health (HNGE) drew fresh investor attention on 4 August 2026 after reporting second quarter earnings, raising full year guidance, updating its share buyback activity, and outlining expansion plans in digital gastrointestinal care. See our latest analysis for Hinge Health. The latest results and acquisition news came on top of strong recent momentum in Hinge Health's stock, with a 1 day share price return of 11.55%, a 7 day share price return of 19.57% and a 90 day share price return of...
NYSE:NPO
NYSE:NPOMachinery

Is Enpro (NPO) Undervalued After Raising 2026 Guidance And Posting Strong Q2 Results?

Why Enpro stock is in focus after raised 2026 guidance Enpro (NPO) is back on investor radars after the company lifted its 2026 revenue growth outlook to a range of 14% to 16%, alongside reporting second quarter 2026 results and affirming its quarterly dividend. See our latest analysis for Enpro. Enpro's raised 2026 guidance and solid second quarter results have come after a strong run, with the share price up 51.9% year to date and supported by a 56.38% 1 year total shareholder return. Multi...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Is Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?

Glaukos (GKOS) is back in focus after reporting record second quarter net sales, supported by iDose TR and the Epioxa launch, and raising its full year 2026 net sales guidance. See our latest analysis for Glaukos. The earnings beat and higher 2026 sales guidance have fed into strong momentum for Glaukos, with a 30 day share price return of 17.69% and year to date share price return of 62.59%. Over a longer horizon, the 1 year total shareholder return of 112.66% suggests recent enthusiasm has...
NasdaqGS:TILE
NasdaqGS:TILECommercial Services

Interface (TILE) Could Be 6% Undervalued Following Earnings And New Sales Guidance

Interface guidance and earnings put recent stock gains in focus Interface (TILE) has just issued new third quarter 2026 sales guidance alongside its second quarter earnings report, giving you fresh numbers to weigh against the stock’s strong recent share price performance. The company now projects third quarter net sales between $370 million and $380 million and has also raised its full year 2026 net sales outlook to a range of $1.455b to $1.485b, slightly above its previous forecast. See our...
NYSE:ABG
NYSE:ABGSpecialty Retail

Asbury Automotive Group (ABG) Reported Q2 Results And Buybacks, Is It A Bargain?

Earnings and Buyback Activity Set the Context for Asbury Automotive Group Stock Asbury Automotive Group (ABG) recently reported second quarter 2026 results, with revenue of US$4,384.6 million and net income of US$114.6 million, alongside ongoing share repurchases under its multi year buyback program. From April to June 2026, the company repurchased 668,000 shares for US$131 million, completing 2,855,333 shares bought back in total. This retirement of stock influences per share metrics and can...